Abstract:Heat shock protein 90 (HSP90) has emerged as an important target in cancer treatment because many of its clients are crucial in malignant transformation. HSP90 inhibitors such as antibiotic anismycin Geldanamycin and its derivatives 17-AAG promote degradation of client proteins. Several preclinical observations have made HSP90 inhibitors attractive drugs to the treatment of cancer. First, HSP90 inhibitors may provide a broader and effective anticancer therapy. Second, HSP90 in tumor cells was shown to exhibit much higher affinity for its inhibitors. HSP90 inhibitors such as 17-AAG and 17-DMAG are currently used targeting a variety of tumors in clinical trials. The TGFβ signaling pathway represents a major tumor suppressor pathway in normal epithelial cells, and paradoxically, it also acts as a significant promoter of tumor progression, invasion and metastasis in carcinomas. Since tumors are often detected in late stages, inhibition of TGFβ signaling pathway may be beneficiary to cancer patients. Several attempts in the past several years have highlighted the potential of blocking TGFβ responses in tumors by using soluble TGFβ receptors or competitive small molecules targeting the TGFβ receptors in anti-cancer therapy. Notably, the toxicity of TGFβ inhibition is well tolerated in mouse models, suggesting the strong potential of anti-TGFβ therapeutics in cancer. Our recent identification that TGFβ receptors are client proteins of HSP90 provides novel insights into the potential of HSP90 inhibitors in anti-cancer therapies. Objective: (1) To elucidate the molecular mechanisms underlying essential role of HSP90 in controlling TGFβ signaling in normal and cancer cells; (2) To explore the potential of HSP90 inhibitors as anti-metastasis therapeutics in breast cancer. Methods: Using a proteomic approach, we found an association between HSP90 and TGFβ receptors (both TβRI and TβRII). Further TβR-HSP90 interaction, TβR turnover and Smad2 phosphorylation were carried out using immunoprecipitation and western blotting. Dosage and duration of treatment with HSP90 inhibitors GA, 17-AAG, and Ridicicol were initially established by evaluating the blockade of TGFβ-induced Smad2 phosphorylation. Effect of HSP90 inhibitors and HSP90 siRNAs on the expression of TGFβ target gene transcription will be assessed by real-time RT-PCR. Cell proliferation was assayed by 3H-thymidine incorporation, and cell invasiveness was done in BD Matrigel Invasion Chambers in MDA-MB-231 breast carcinoma cells. Results: Using biochemical assays, we confirmed that TGFβ receptors (both TβRI and TβRII) physically associated with HSP90 proteins in a variety of normal and cancer cells. We next found that inhibition of HSP90 functions by several HSP90 inhibitors can promote the rapid turnover of TGFβ receptors in a ubiquitination/proteasome-dependent manner. Consequently, HSP90 inhibitors inhibit TGFβ-mediated phosphorylation of tumor suppressors SMAD2 and SMAD3, and block TGFβ-dependent transcription of genes such as MMP9. At the cellular level, HSP90 inhibitors led to the blockade of TGFβ-induced invasiveness of MDA-MB-231 breast carcinoma cells. Conclusion: We have identified HSP90 inhibitors as potential drugs blocking TGFβ functions. This study should help to understand the mechanisms of TGFβ and HSP90 interplay in progression of human cancers. Our study will also provide invaluable information on the use of HSP90 inhibitors for the treatment of human cancers.

BJ-B11, an Hsp90 Inhibitor, Constrains the Proliferation and Invasion of Breast Cancer Cells

The selective Hsp90 inhibitor BJ-B11 exhibits potent antitumor activity via induction of cell cycle arrest, apoptosis and autophagy in Eca-109 human esophageal squamous carcinoma cells

Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics

Targeting HSP 90-HDAC 6 Regulating Network Implicates Precision Treatment of Breast Cancer

QS288. Potent Blockade of TGF-β Signaling by HSP90 Inhibitors

Short-hairpin RNA-mediated Heat Shock Protein 90 Gene Silencing Inhibits Human Breast Cancer Cell Growth in Vitro and in Vivo

AT-533, a Novel Hsp90 Inhibitor, Inhibits Breast Cancer Growth and HIF-1α/VEGF/VEGFR-2-mediated Angiogenesis in Vitro and in Vivo.

HSPB1 Facilitates Chemoresistance Through Inhibiting Ferroptotic Cancer Cell Death and Regulating NF-κB Signaling Pathway in Breast Cancer

Alkaloid Derivative ION-31a Inhibits Breast Cancer Metastasis and Angiogenesis by Targeting HSP90α.

Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and in vitro Studies

Identification of HSP90B1 in pan-cancer hallmarks to aid development of a potential therapeutic target

Inhibition of HSP90 Sensitizes a Novel Raf/ERK Dual Inhibitor CY-9d in Triple-Negative Breast Cancer Cells

FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation

Targeting HSP90 Inhibits Proliferation and Induces Apoptosis Through AKT1/ERK Pathway in Lung Cancer

Bj-B11, A Novel Hsp90 Inhibitor, Induces Apoptosis in Human Chronic Myeloid Leukemia K562 Cells Through the Mitochondria-Dependent Pathway

Extracellular Hsp90 Promotes Tumor Lymphangiogenesis and Lymph Node Metastasis in Breast Cancer

Discovery of Potent Heat Shock Protein 90 (hsp90) Inhibitors: Structure-Based Virtual Screening, Molecular Dynamics Simulation, and Biological Evaluation

Expression of heat shock protein 70 in breast cancer and its effect on the biological function of breast cancer cells in vitro

Hsp90 Inhibits Apoptosis And Promotes Growth By Regulating Hif-1 Alpha Abundance In Hepatocellular Carcinoma

HSP90AB1 Promotes the Proliferation, Migration, and Glycolysis of Head and Neck Squamous Cell Carcinoma

Study on the Effect of HSP90 Inhibitor IPI-504 on Gastric Cancer Cells and Its Stem Cell Like Cells